BRIEF-Abivax says primary endpoint of ABX203 Phase IIb/III trial unlikely to be reached

* Analysis of ongoing ABX203 Phase IIb/III trial in chronic Hepatitis B virus infection

shows good safety, but primary endpoint of study is unlikely to be reached

Read more